Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic alpha-interferon therapy of multiple sclerosis.

R L Knobler, H S Panitch, S L Braheny

    Neurology
    |October 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.

    Clinical pharmacology and therapeutics·2013
    Same author

    Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

    The pharmacogenomics journal·2009
    Same author

    Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects.

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
    Same author

    A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2006
    Same author

    Cardiac troponins and chronic kidney disease.

    Kidney international·2006
    Same author

    Plasma BNP concentration predicted the presence of heart failure.

    Evidence-based cardiovascular medicine·2005

    Natural alpha interferon may reduce relapses in some patients with relapsing-remitting multiple sclerosis (MS). Further research is needed to confirm its efficacy and optimal use in MS treatment.

    Area of Science:

    • Neurology
    • Immunology
    • Pharmacology

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Exacerbating-remitting MS (RRMS) is characterized by distinct attacks followed by recovery periods.
    • Effective treatments for RRMS aim to reduce relapse frequency and severity.

    Purpose of the Study:

    • To evaluate the efficacy of natural alpha interferon in managing exacerbating-remitting multiple sclerosis.
    • To assess the impact of interferon on relapse rates and severity in RRMS patients.

    Main Methods:

    • A randomized, double-blind, placebo-controlled crossover study design.
    • Twenty-four RRMS patients received 6-month treatment periods of daily natural alpha interferon (5 x 10^6 IU) or placebo.

    Related Experiment Videos

  • A 6-month washout period separated the treatment phases.

    • Main Results:

    • Both interferon and placebo reduced exacerbation rates compared to pre-study levels.
    • Interferon demonstrated a greater reduction in exacerbations, especially after a placebo phase, suggesting a potential learning effect.
    • Patients with strictly RRMS experienced fewer and milder relapses on interferon versus placebo.
    • Patients with a progressive component of MS showed continued disease activity.

    Conclusions:

    • Natural alpha interferon may reduce exacerbations in specific subgroups of MS patients.
    • The findings suggest potential therapeutic benefits of interferon for RRMS.
    • Guidelines for future interferon trials in MS are indicated based on patient characteristics.